• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
ZHU Liping,WEI Xuxia,HAO Lina,XUE Ning,LI Xia.Efficacy and safety of infliximab in the treatment of ulcerative colitis in children[J].Journal Of Pharmaceutical Research,2024,43(5):504-508[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2909times   Download 2676次 QR Code for this article
Scan with your phone!
英夫利西单抗治疗儿童溃疡性结肠炎的疗效及安全性
朱立平1,魏绪霞1,郝丽娜1,薛宁1,李霞2
Font:Larger+|Default|Smaller-
(1.济南市儿童医院,山东 济南 250022;2.山东省药品不良反应监测中心,山东 济南 250014)
摘要:
目的 评价英夫利西单抗(infliximab,IFX)治疗儿童溃疡性结肠炎(ulcerative colitis,UC)的疗效以及安全性。方法 回顾性分析2018年1月至2022年12月在济南市儿童医院接受IFX治疗的21例溃疡性结肠炎患儿临床资料。比较治疗前后儿童UC疾病活动指数(pediatric ulcerative colitis activity index,PUCAI)、内镜严重程度评分和实验室检查结果,评估IFX疗效及安全性。结果 21例UC患儿中男12例、女9例。IFX疗效分析显示,第14周诱导缓解期临床应答率76.2%(16/21),临床缓解率66.7%(14/21)。第30周维持缓解期临床应答率76.4%(13/17),持续缓解率58.5%(10/17)。与治疗前相比,IFX治疗第14周及30周PUCAI、C反应蛋白(C reactive protein,CRP)、红细胞沉降率(erythrocyte sedimentation rate,ESR)、粪便钙卫蛋白均明显下降(P<0.05),血红蛋白、白蛋白均有显著改善(P<0.05)。14周复查结肠镜,8例达到黏膜愈合,6例由重度炎症减轻为中度炎症,4例黏膜炎症中度炎症减轻为轻度炎症,2例黏膜炎症无好转。IFX输液反应发生率为 43%(9/21),包括急性输液反应、迟发性输液反应、转氨酶升高,其中治疗期间感染最常见,发生率为38%(8/21)。结论 IFX对儿童UC疗效显著,但治疗期间需警惕不良事件的发生。
关键词:  英夫利西单抗  儿童  溃疡性结肠炎  疗效  不良反应
DOI:10.13506/j.cnki.jpr.2024.05.015
基金项目:山东省药品化妆品不良反应监测哨点课题(No.2022SDADRKY02)
Publication Date:May 25, 2024
Efficacy and safety of infliximab in the treatment of ulcerative colitis in children
ZHU Liping1,WEI Xuxia1,HAO Lina1,XUE Ning1,LI Xia2
(1.Department of Jinan Children's Hospital,Jinan 250022,China;2.Department of Shandong Provincial Adverse Center for ADR Monitoring,Jinan 250014,China)
Abstract:
Objective To evaluate the efficacy and safety of infliximab (IFX) in children with ulcerative colitis (UC). Methods The clinical data of 21 children with ulcerative colitis who received IFX at Jinan Children's Hospital from January 2018 to December 2022 were analyzed retrospectively.The pediatric ulcerative colitis activity index(PUCAI)、ulcerative colitis endoscopic index of severity and laboratory findings were compared to assess the efficacy and safety of IFX. Results There were 12 males and 9 females among 21 children with UC. IFX efficacy analysis showed that the clinical response rate at week 14 was 76.2% (16/21) and the clinical response rate was 66.7% (14/21). The clinical response rate in maintained remission at week 30 was 76.4% (13/17) and the sustained response rate was 58.5% (10/17). PUCAI score, C reactive protein, erythrocyte sedimentation rate and fecal calprotectin were significantly decreased in 14 and 30 weeks of IFX treatment compared with before treatment (P<0.05), and hemoglobin and albumin were significantly improved (P<0.05). At 14 weeks,8 cases achieved mucosal healing,6 cases reduced severe mucosal inflammation to moderate inflammation, 4 cases reduced moderate inflammation to mild inflammation, and 2 cases showed no improvement in mucosal inflammation.The incidence of IFX infusion reactions was 43%(9/21),including acute infusion reactions,delayed infusion reactions,and transaminase elevation.Infections were the most common during treatment, with an incidence of 38% (8/21).Conclusion IFX is effective on UC in children, However, we should be alert to the occurrence of adverse events during the treatment.
Key words:  Infliximab  Children  Ulcerative colitis  Efficacy  Adverse effects
Today's Visits:527    Total Visits:2383269
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.